Of note, Erlotinib is highly effective in inhibiting EGFR with kinase domain mutations that are prevalent in lung cancer [260] as opposed to its low efficacy in blocking EGFR with extracellular domain mutations that are characteristic of GBM [261,262]. Here, EGFR is linked to lung cancer.